IPSC · Century Therapeutics, Inc.
$1.53
-0.08 (-4.97%)
At close · Oct 2
Return incl. dividend (before tax)
Market Cap
$302.40M
Shares
181.08M
Volume · Oct 2
802.96K
Avg daily vol (3M)
643.93K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.53
Open$1.64
Day$1.47–1.67
52W close$0.47–2.94
Avg vol 30d489K
Short int29.4M · 16.2% float · 78.6d
Short vol42%
Last earningsMar 19, 2025
DataJun 2021–Oct 2026
Filing10-Q · Aug 12
Up next
filed Aug 12, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$114.90M
Trailing 12 months
Net income (TTM)
−$109.79M
Trailing 12 months
Revenue growth YoY
+12,667.7%
Year over year
Operating margin
-15.8%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+138.6%
Year over year · more shares
Price change (1Y)
+207.2%
Trailing year
Short interest
16.2%
Latest settlement · 78.6 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−26%
below
Price vs 50-day avg
−22%
below
RSI (14)
28
oversold
MACD trend
Negative
52-week position
43%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−27%
trailing
6-month return
−33%
trailing
YTD return
+54%
this year
Relative strength
−45%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
+36% holders QoQ · +37 funds added
Insider flow
Distributing
Net -$10.4K over 90 days · 100% sells
Short interest
Falling
16.21% of float · ▼ -0.6% MoM · 78.6 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
101 holders — near 3-yr high, broad support
Squeeze score
64
elevated · 0–100
Fundamentals
Revenue growth
+1557%
Y/Y
EPS growth
+91%
Y/Y
Free cash flow
$-104.7M
Balance sheet
$74.0M
net cash
Quant / Vol
risk profile
Volatility
98%
annualized · 1-yr
Max drawdown
−48%
past year
ATR
7.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 11, 2023
GAAP operating expenses
· full year
GAAP
$135M – $145M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−26%
Bearish
Price vs 50-day avg
−22%
Bearish
RSI (14)
28
Neutral
MACD trend
Negative
Bearish
52-week position
43%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
+36% holders QoQ · +37 funds added
Insider flow
Distributing
Net -$10.4K over 90 days · 100% sells
Short interest
Falling
16.21% of float · ▼ -0.6% MoM · 78.6 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
101 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $0
Now $2 · 43%
Range high $3
vs 200-day avg -26%
vs 50-day avg -22%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IPSC
this stock
Century Therapeutics, Inc.
|
$302.40M | +53.8% | +1556.8% | — | 16.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IPSC | -8.4% | -26.8% | -32.6% | -10.5% | +53.8% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -8.2% | -26.3% | -44.8% | -11.5% | +40.9% |